文献速递浆细胞疾病造血干细胞移植与细胞治疗

靶向多发性骨髓瘤的复合嵌合抗原受体策略

A compound chimeric antigen receptor strategy for targeting multiple myeloma.
PubMed 文献 · Leukemia · 2017-09-27

针对多发性骨髓瘤的B细胞成熟抗原(BCMA)嵌合抗原受体(CAR)T细胞治疗后易因抗原阳性或阴性细胞再出现而复发,本研究构建了同时靶向BCMA和CS1的双独立CAR受体的复合CAR(cCAR)T细胞,体外显示对两种靶抗原群体均有强效定向细胞毒性,小鼠模型中体内存活优于单表达CAR T细胞。

要点

  • 复合CAR T细胞同时靶向多发性骨髓瘤抗原BCMA和CS1
  • cCAR T细胞对每种靶抗原群体均具有一致、强效且定向的细胞毒性
  • 小鼠模型中cCAR T细胞体内存活优于单表达CAR T细胞

核心结论

  • 复合靶向骨髓瘤细胞上的BCMA和CS1可能成为增强对骨髓瘤 bulk 疾病应答及启动更广泛覆盖CAR治疗的有效策略。

研究设计与样本

  • 研究报道了同时靶向多发性骨髓瘤抗原BCMA和CS1、携带两个完整独立CAR受体的CAR T细胞的抗肿瘤活性,并使用多种骨髓瘤小鼠模型和混合细胞群体进行体内评价。

主要发现

  • 复合CAR(cCAR)T细胞对每种靶抗原群体均具有一致、强效且定向的细胞毒性。
  • 在多种骨髓瘤小鼠模型和混合细胞群体中,cCAR T细胞通过定向细胞毒性对多种细胞群体的体内存活优于单表达CAR T细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current clinical outcomes using chimeric-antigen receptors (CARs) against multiple myeloma show promise in the eradication of bulk disease. However, these anti-BCMA (CD269) CARs observe relapse as a common phenomenon after treatment due to the reemergence of either antigen-positive or -negative cells. Hence, the development of improvements in CAR design to target antigen loss and increase effector cell persistency represents a critical need. Here, we report on the anti-tumor activity of a CAR T-cell possessing two complete and independent CAR receptors against the multiple myeloma antigens BCMA and CS1. We determined that the resulting compound CAR (cCAR) T-cell possesses consistent, potent and directed cytotoxicity against each target antigen population. Using multiple mouse models of myeloma and mixed cell populations, we are further able to show superior in vivo survival by directed cytotoxicity against multiple populations compared to a single-expressing CAR T-cell. These findings indicate that compound targeting of BCMA and CS1 on myeloma cells can potentially be an effective strategy for augmenting the response against myeloma bulk disease and for initiation of broader coverage CAR therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Chen KH, Wada M, Pinz KG, et al. A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia. 2017. PMID: 28951562. doi:10.1038/leu.2017.302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。